OTOVEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OTOVEL (OTOVEL).
Otic antibiotic and anti-inflammatory combination: ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, while fluocinolone acetonide suppresses inflammation by binding to glucocorticoid receptors and inhibiting phospholipase A2.
| Metabolism | Ciprofloxacin: hepatic metabolism via CYP1A2 to minor metabolites (desethylene-ciprofloxacin, sulfociprofloxacin, oxociprofloxacin); fluocinolone: hepatic metabolism via CYP3A4. |
| Excretion | Primarily excreted unchanged in feces (~60%) and urine (~15%). Biliary elimination accounts for ~20% of the total clearance. |
| Half-life | Terminal half-life is approximately 10-12 hours in healthy adults. In patients with cholestasis, the half-life may be prolonged up to 20 hours due to enterohepatic recirculation impairment. |
| Protein binding | Approximately 90% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5 L/kg, indicating distribution into total body water and tissues. Due to topical otic use, systemic Vd is not clinically relevant; local tissue distribution is limited to the ear canal and middle ear. |
| Bioavailability | Topical otic: approximately 15% systemically absorbed through the inflamed tympanic membrane. Oral bioavailability not applicable; only approved for otic use. |
| Onset of Action | Therapeutic effect (resolution of otic symptoms) typically begins within 24-48 hours of topical administration. Initial improvement in otorrhea may be seen as early as 12 hours. |
| Duration of Action | Clinical effect lasts for the duration of treatment (typically 7 days). Drug concentrations at the site of action are maintained due to mucosal adherence and slow release from the ear canal tissue. |
Apply 4 drops to the affected ear(s) twice daily for 7 days.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No adjustment required for any degree of renal impairment. |
| Liver impairment | No adjustment required for any degree of hepatic impairment. |
| Pediatric use | For children 6 months and older: 4 drops into the affected ear(s) twice daily for 7 days. |
| Geriatric use | No specific dose adjustment; use standard adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OTOVEL (OTOVEL).
| Breastfeeding | Unknown whether ciprofloxacin or hydrocortisone are excreted in human milk after topical otic administration. Systemic ciprofloxacin is excreted in breast milk; however, topical application is unlikely to result in significant systemic absorption. Caution should be exercised when administered to a nursing woman. M/P ratio not available for topical formulation. |
| Teratogenic Risk | Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, topical administration of ciprofloxacin/hydrocortisone at doses up to 6 times the human dose during organogenesis did not reveal evidence of teratogenicity. However, systemic fluoroquinolones have been associated with arthropathy in immature animals. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: theoretical risk of quinolone-induced cartilage damage; avoid unless essential. Second/third trimester: limited data; consider alternative therapy. |
■ FDA Black Box Warning
Not for ophthalmic use. For otic use only.
| Serious Effects |
Hypersensitivity to ciprofloxacin, fluocinolone acetonide, or any component; viral or fungal otic infections; tympanic membrane perforation (relative); concurrent use with systemic fluoroquinolones (relative).
| Precautions | Hypersensitivity reactions including anaphylaxis; prolonged use may result in overgrowth of non-susceptible organisms; discontinue if irritation or sensitization occurs; not for use in patients with viral or fungal otic infections; avoid contact with eyes. |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required; observe for maternal signs of systemic toxicity (e.g., hypersensitivity, local irritation). If prolonged use, monitor for ototoxicity or superinfection. No routine laboratory monitoring indicated. |
| Fertility Effects | No studies on fertility effects with topical otic ciprofloxacin/hydrocortisone. Systemic fluoroquinolones have been associated with reversible impairment of fertility in animal studies at high doses. Clinical relevance for topical otic use is negligible due to minimal systemic absorption. |